SoftOx Solutions raised NOK 50 million in a private placement after the stock exchange closed on Wednesday this week.
According to an announcement from the company Friday, the interest was huge, and the issue of shares was more than 100 percent oversubscribed.
– This clearly shows that we have confidence in the market, that we are on the right track and it will give us the power we need for our further investment. There is a lot of exciting happening, both in product development and commercialization, both nationally and internationally, says CEO Geir Almås of SoftOx Solutions in the report.
The company now wants a repair issue of up to NOK 10 million to give shareholders who did not have the opportunity to participate in the private placement the opportunity to subscribe to the same terms as in the private placement – and thus partly “repair” the dilution in ownership.
According to the company, the money contributes to funding further research, including the ongoing lung studies at the University of Copenhagen, where the company’s goal is to start testing on humans as early as 2021.
The company will now also be able to intensify its activities related to the investment in the company’s non-alcoholic and skin-friendly hand sanitizer AntiVir and SafeDes towards several large markets in Europe and Asia.